Search filters

Filters

Clear All

Phase

  • 67
  • 71
  • 1
  • 86
  • 1
  • 61
  • 13
  • 203
  • 578
  • 220
  • 9
  • 25
  • 548
  • 578
  • 4

Found 582 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Phase 1 Study of the Highly-selective RET

A Phase 1 Study of the Highly-selective RET

All genders
Phase 1
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …
 A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

18 years - 98 years
All genders
Phase 2
The BBI-DSP-7888-201G trial is designed to compare the overall survival (OS) between treatment with DSP-7888 Dosing Emulsion plus bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following initial therapy. This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study. Approximately 200 patients …
 11C-Trimethoprim PET/CT imaging to evaluate biodistribution and kinetics in human subjects

11C-Trimethoprim PET/CT imaging to evaluate biodistribution and kinetics in human subjects

18 years - 99 years
All genders
Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 30 subjects will …

The Randomized And Controlled Non-inferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-Coated Balloon

All genders
Prospective, multi-center, single-blind, randomized, controlled, noninferiority clinical trial. The trial will randomize approximately 446 subjects (at approximately 60 sites in the US and 18 sites outside the US) with symptomatic PAD due to stenoses of the femoral and/or popliteal arteries. Subjects meeting eligibility criteria will be randomized 1:1 to treatment …

A Randomized Placebo Surgery Controlled Double-blinded Multi-center Phase 2 Clinical Trial Evaluating Efcacy and Safety of VY-AADC02 in Advanced Parkinsons Disease with Motor Fluctuations

All genders
Phase 2
The main purpose of this study is to test the safety and efcacy (how well it works) of an experimental intervention called VY-AADC02 on the severity of PD. VY-AADC02 involves placing a gene in the brain that programs brain cells to produce an enzyme (protein) called AADC (aromatic amino acid …
 Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional  Recurrent Head and Neck Squamous Cell Carcinoma

Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional Recurrent Head and Neck Squamous Cell Carcinoma

18 years - 99 years
All genders
Phase 3
This is a Phase 3, randomized, double-arm, open-label trial of ASP-1929 photoimmunotherapy (ASP-1929 PIT) versus physician's choice standard of care (SOC) for the treatment of locoregional, recurrent head and neck squamous cell carcinoma (HNSCC) in patients who have failed or progressed on or after at least two lines of therapy, …
 PRELIMINARY STUDY OF OPTICAL BIOMARKERS FOR NEURODEGENERATION IN CHRONIC CEREBROVASCULAR DISEASE

PRELIMINARY STUDY OF OPTICAL BIOMARKERS FOR NEURODEGENERATION IN CHRONIC CEREBROVASCULAR DISEASE

All genders
This research study will test whether a new optical device can reliably measure markers of blood flow and blood vessel function in the brain. We will be recruiting 60 subjects in total: 30 healthy, 15 with known narrowing of the carotid artery, and 15 small vessel stroke. All subjects will …

Transseptal vs. Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli Multi-center comparative effectiveness randomized clinical trial to assess a transeptal approach to left ventricular ablation compared to a retrograd aortic aproach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tacht=ycardia (VT) and /or premature ventricular contractions (PVCs)

All genders
Both transseptal and retrograde aortic approaches are routinely utilized in pediatric and adult cardiac electrophysiology and cardiac catheterization laboratories in the United States and have been in clinical practice for decades to treat multiple types of left atrial and ventricular arrhythmias. As either approach can be used to perform catheter …
 A Multiple-Site  Phase 1/2  Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

A Multiple-Site Phase 1/2 Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

All genders
Phase 2
Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 50% are caused …

UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer

All genders
Phase 2
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer …
251 - 260 of 582